<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mosley, Mary</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Packer, Milton</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">PARADIGM-HF: Novel Drug Reduced Outcomes, Improved Symptoms Better Than ACE Inhibition</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">11-12</style></pages><abstract><style  face="normal" font="default" size="100%">A greater reduction in cardiovascular (CV) death or heart failure (HF) hospitalization was achieved with an investigational drug, LCZ696, than with enalapril. This article discusses The Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure trial [PARADIGM-HF; McMurray JJV et al. N Engl J Med. Published online August 30, 2014]</style></abstract><number><style face="normal" font="default" size="100%">27</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>